UNSPSC 51313601: Minocromil

This classification denotes a histamine-1 receptor antagonist with the molecular formula C18H16N2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F37A9VKY5Q, chemically known as 6-(methylamino)-4-oxo-10-propyl-4h-pyrano(3,2-g)quinoline-2,8-dicarboxylic acid but generally known as minocromil, which bears US NIH Compound Identifier 71448. European Medicines Agency schedules Minocromil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08979MIG.

UNSPSC 51313601 Minocromil is a Commodity code under which state and local governments procure pharmaceutical products, though recent solicitations show this specific drug-code designation appearing alongside broader pharmaceutical procurement activity. State and local issuing bodies soliciting under and near this code include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The work spans standalone pharmaceutical purchases for community health initiatives through cooperative statewide contracting vehicles that aggregate demand across numerous public entities. Seminole County, Florida, for example, recently issued IFB 60459723LAS seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to support community health initiatives, while the Texas Health and Human Services Commission posted RFI HHS0017013 to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager and wholesale channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products across participating state and local government facilities, including Oregon, with pricing evaluations weighted 75 percent on price competitiveness and submissions due March 26, 2026.

Recent activity concentrates in Florida, Texas, and Minnesota, though MMCAP's multi-state structure extends reach across participating jurisdictions. The Seminole County IFB required vendors to meet drug-free workplace certification, E-Verify compliance, and specific insurance coverage including workers' compensation and commercial general liability, with a two-year initial term and one-year renewal option, potentially funded through FEMA with associated federal regulatory compliance obligations. MMCAP's RFP requires manufacturer certification under current Good Manufacturing Practices and the Drug Supply Chain Security Act, contractual relationships with at least two of three authorized wholesalers, and commercial general liability of $5 million per occurrence, with a two-year contract term and optional extensions. The Texas RFI, posted April 3, 2026, functions as market intelligence gathering and does not represent an immediate procurement opportunity but signals future state-level demand for direct pharmaceutical supply models outside traditional PBM and wholesaler relationships.